Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Min Han Tan

Showing results (111-120 of 147) with videos related to

Pageof 15
Sort By:
Human Genomics|November 24, 2022
Whole-exome sequencing of BRCA-negative breast cancer patients and case-control analyses identify variants associated with breast cancer susceptibilityNing Yuan Lee, Melissa Hum, Aseervatham Anusha Amali, et al.
Clinical Epigenetics|May 15, 2024
Machine learning unveils an immune-related DNA methylation profile in germline DNA from breast cancer patientsNing Yuan Lee, Melissa Hum, Guek Peng Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinomaMin-Han Tan, Carl Morrison, Pengfei Wang, et al.
The Lancet. Oncology|January 15, 2013
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyDaniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
BMC Bioinformatics|December 5, 2020
Regional registration of whole slide image stacks containing major histological artifactsMahsa Paknezhad, Sheng Yang Michael Loh, Yukti Choudhury, et al.
Biomaterials|February 17, 2019
Polymers with distinctive anticancer mechanism that kills MDR cancer cells and inhibits tumor metastasisGuansheng Zhong, Chuan Yang, Shaoqiong Liu, et al.
Cancer Cell|October 22, 2011
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinomaAikseng Ooi, Jing-Chii Wong, David Petillo, et al.
The Lancet. Oncology|August 11, 2012
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based studyLauren C Harshman, Wanling Xie, Georg A Bjarnason, et al.
Targeted Oncology|January 10, 2013
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patientsMhd Y Al-Marrawi, Brian I Rini, Lauren C Harshman, et al.
Clinical Genitourinary Cancer|February 4, 2014
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinomaNimira Alimohamed, Jae-Lyn Lee, Sandy Srinivas, et al.
Pageof 15

Showing results (111-120 of 147) with videos related to

Sort By:
Pageof 15
Human Genomics|November 24, 2022
Whole-exome sequencing of BRCA-negative breast cancer patients and case-control analyses identify variants associated with breast cancer susceptibilityNing Yuan Lee, Melissa Hum, Aseervatham Anusha Amali, et al.
Clinical Epigenetics|May 15, 2024
Machine learning unveils an immune-related DNA methylation profile in germline DNA from breast cancer patientsNing Yuan Lee, Melissa Hum, Guek Peng Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinomaMin-Han Tan, Carl Morrison, Pengfei Wang, et al.
The Lancet. Oncology|January 15, 2013
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyDaniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
BMC Bioinformatics|December 5, 2020
Regional registration of whole slide image stacks containing major histological artifactsMahsa Paknezhad, Sheng Yang Michael Loh, Yukti Choudhury, et al.
Biomaterials|February 17, 2019
Polymers with distinctive anticancer mechanism that kills MDR cancer cells and inhibits tumor metastasisGuansheng Zhong, Chuan Yang, Shaoqiong Liu, et al.
Cancer Cell|October 22, 2011
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinomaAikseng Ooi, Jing-Chii Wong, David Petillo, et al.
The Lancet. Oncology|August 11, 2012
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based studyLauren C Harshman, Wanling Xie, Georg A Bjarnason, et al.
Targeted Oncology|January 10, 2013
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patientsMhd Y Al-Marrawi, Brian I Rini, Lauren C Harshman, et al.
Clinical Genitourinary Cancer|February 4, 2014
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinomaNimira Alimohamed, Jae-Lyn Lee, Sandy Srinivas, et al.
Pageof 15